LSM2 and breast carcinoma: Specifically, LSM2 is part of a hetero-oligomeric complex that facilitates the binding of RNA to small nuclear ribonucleoproteins (snRNPs), ensuring efficient splicing and RNA stability Dysfunction in LSM2 has been implicated in several cancers, such as breast cancer and hepatocellular carcinoma, suggesting its potential as a biomarker and therapeutic target (10, 11).